PARLIAMENTARY WRITTEN QUESTION
(27 March 2025)

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of implementing nurse-led mobile PSA blood testing clinics in deprived communities on (a) costs to and (b) staff productivity in the NHS.

Asked by:
Helen Maguire (Liberal Democrat)

Tackling health inequalities is a priority for the Government. Men aged 50 years old or over can ask their general practitioner for a Prostate-Specific Antigen (PSA) test, even if they do not have symptoms. This applies to anyone aged 50 years old or over in any part of England.

Screening for prostate cancer is currently not recommended in the United Kingdom. This is because of the inaccuracy of the current best test. Whilst it is recognised that the PSA test can be a valuable diagnostic tool in certain contexts, such as for men who present with symptoms, its limitations mean it is not currently recommended for population-level screening.

We are finding the best way to test for prostate cancer, which is why we are investing £16 million towards the Prostate Cancer UK led TRANSFORM screening trial, which is seeking to find better ways of catching prostate cancer in men.

The UK National Screening Committee, an independent scientific committee which advises ministers on screening, is also currently reviewing the evidence for both population wide screening and targeted prostate cancer screening. If the UK National Screening Committee makes a positive recommendation regarding screening for prostate cancer, an impact assessment will be produced using the HM Treasury Green Book methodology, which considers wider social and economic impacts.

Answered by:
()